Key result
SIRT2 overexpression protects against Ang II-induced cardiac hypertrophy and dysfunction via LKB1-AMPK activation.
Why the study?
Does SIRT2 protect against aging-related and angiotensin II-induced pathological cardiac hypertrophy and preserve cardiac function in murine models?
Does SIRT2 protect against aging-related and angiotensin II-induced pathological cardiac hypertrophy and preserve cardiac function in murine models?
This preclinical study identifies the deacetylase SIRT2 as a key cardioprotective regulator that prevents aging- and stress-induced cardiac hypertrophy by activating the LKB1-AMPK pathway, and demonstrates that SIRT2 is required for the cardioprotective effects of metformin.
Answers are grounded in this paper and cite their sources.
SIRT2 activation does not support clinical use; leaves open whether LKB1-AMPK targeting benefits patients with cardiac hypertrophy.
Background: Pathological cardiac hypertrophy induced by stresses such as aging and neurohumoral activation is an independent risk factor for heart failure and is considered a target for the treatment of heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. We aimed to investigate the roles of SIRT2 in aging-related and angiotensin II (Ang II)–induced pathological cardiac hypertrophy. Methods: Male C57BL/6J wild-type and Sirt2 knockout mice were subjected to the investigation of aging-related cardiac hypertrophy. Cardiac hypertrophy was also induced by Ang II (1.3 mg/kg/d for 4 weeks) in male C57BL/6J Sirt2 knockout mice, cardiac-specific SIRT2 transgenic ( SIRT2 -Tg) mice, and their respective littermates (8 to ≈12 weeks old). Metformin (200 mg/kg/d) was used to treat wild-type and Sirt2 knockout mice infused with Ang II. Cardiac hypertrophy, fibrosis, and cardiac function were examined in these mice. Results: SIRT2 protein expression levels were downregulated in hypertrophic hearts from mice. Sirt2 knockout markedly exaggerated cardiac hypertrophy and fibrosis and decreased cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and Ang II–infused mice. Conversely, cardiac-specific SIRT2 overexpression protected the hearts against Ang II–induced cardiac hypertrophy and fibrosis and rescued cardiac function. Mechanistically, SIRT2 maintained the activity of AMP-activated protein kinase (AMPK) in aged and Ang II–induced hypertrophic hearts in vivo as well as in cardiomyocytes in vitro. We identified the liver kinase B1 (LKB1), the major upstream kinase of AMPK, as the direct target of SIRT2. SIRT2 bound to LKB1 and deacetylated it at lysine 48, which promoted the phosphorylation of LKB1 and the subsequent activation of LKB1-AMPK signaling. Remarkably, the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function. Conclusions: SIRT2 promotes AMPK activation by deacetylating the kinase LKB1. Loss of SIRT2 reduces AMPK activation, promotes aging-related and Ang II–induced cardiac hypertrophy, and blunts metformin-mediated cardioprotective effects. These findings indicate that SIRT2 will be a potential target for therapeutic interventions in aging- and stress-induced cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2017) studied Pathological cardiac hypertrophy (aging-related and angiotensin II-induced). Cardiac-specific SIRT2 overexpression, Sirt2 knockout, and metformin vs. Wild-type / non-transgenic littermates and saline / vehicle control was evaluated on Cardiac hypertrophy, myocardial fibrosis, and cardiac function (ejection fraction and fractional shortening). SIRT2 overexpression protected mice against angiotensin II-induced cardiac hypertrophy and fibrosis and rescued cardiac function by deacetylating LKB1 at lysine 48 to activate AMPK signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: